论文部分内容阅读
目的观察国产重组人胰升血糖素样肽—1(rhGLP-1)联合西格列汀对糖尿病犬降糖效果。方法对T2DM犬予单次rhGLP-1(G组)、西格列汀(S组)或rhGLP—1联合西格列汀(GS组)及连续2周rhGLP-1联合西格列汀治疗(2wGS组);与对照(Ctr组)比较,观察其OGTT后血糖、血GLP-1、胰岛素、胰升血糖素水平的变化。结果与Ctr对照组比较,G、S和GS组血糖下降不明显。2wGS治疗组OGTT血糖曲线下面积(AUC)降低(2710.1 vs 1238.4 min·mmol/L,P<0.05);血GLP-1浓度在30min(14.9vs125.4 pmol/L)、60 min(18.9vs359.7 pmol/L)和120 min(8.7 vs 88.7 pmol/L)均升高(P<0.05);糖负荷后30 min胰岛素分泌峰值升高(2.39 vs9.87μU/ml,P<0.05)、血胰升血糖素降低(10.60vs3.79 ng/ml,P<0.05)。结论国产rhGLP—1联合西格列汀治疗两周,能增加胰岛素分泌、抑制胰升血糖素分泌,使血糖水平降低。
Objective To observe the effect of domestic recombinant human glucagon-like peptide-1 (rhGLP-1) and sitagliptin on diabetic hypoglycemic mice. Methods T2DM dogs were treated with rhGLP-1 (group G), sitagliptin (group S) or rhGLP-1 combined with sitagliptin (group GS) and continuous 2-week rhGLP-1 plus sitagliptin 2wGS group). Compared with control group (Ctr group), the changes of blood glucose, blood GLP-1, insulin and glucagon were observed after OGTT. Results Compared with Ctr control group, there was no obvious decrease of blood glucose in G, S and GS groups. The area under the curve of blood glucose (OGTT) of 2wGS treatment group was lower (2710.1 vs 1238.4 min · mmol / L, P <0.05); the GLP-1 concentration of blood was 30 min (14.9 vs 125.4 pmol / L) and 60 min (18.9 vs 359) 7 pmol / L) and 120 min (8.7 vs 88.7 pmol / L), respectively (P <0.05). The peak of insulin secretion at 30 min after glucose load increased (2.39 vs 9.87 μU / ml, P < Glucagon decreased (10.60 vs 3.79 ng / ml, P <0.05). Conclusion Domestic rhGLP-1 combined with sitagliptin for two weeks can increase insulin secretion, inhibit glucagon secretion and decrease blood glucose level.